Use of b-cell lymphoma 2 (bcl-2) inhibitor and pharmaceutical composition for treating cellular senescence-related skin diseases

Abstract

The present disclosure discloses use of a B-cell lymphoma 2 (BCL-2) inhibitor for treating cellular senescence-related skin diseases and a pharmaceutical composition for treating the cellular senescence-related skin diseases, belonging to the technical field of medicine. In the present disclosure, studies have found that pharmaceutical compositions containing the BCL-2 inhibitor can significantly ameliorate skin erythema and scale in imiquimod-induced psoriasis mouse models, significantly reduce a thickness of skin lesions, and decrease expression of cellular senescence-related proteins P16 and P21 and mRNA expression levels of p16, p21 and other genes in the skin lesions of the psoriasis mouse models. In addition, the pharmaceutical composition containing the BCL-2 inhibitor can significantly reduce infiltration of CD4+ T cells in dermis of the skin lesions of the psoriasis mouse models, and mRNA expression levels of skin lesion inflammatory factors such as IFN-γ, IL-17A, IL-22 and IL-23.

Dependencies are inferred from the claim text.